2024
GP100 expression is variable in intensity in melanoma
Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.Peer-Reviewed Original ResearchConceptsGp100 expressionCutaneous melanomaTreatment of cutaneous melanomaAdvanced cutaneous melanomaT-cell engagersImprove patient selectionMetastatic melanomaUveal melanomaMetastatic samplesPatient selectionClinical trialsMelanomaQuantitative immunofluorescence methodGp100Improve outcomesImmunofluorescence methodTherapeutic intentDrugCellular productsExpressionTebentafuspImmunohistochemistry
2013
Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, Kluger HM. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clinical Pathology 2013, 13: 3. PMID: 23374878, PMCID: PMC3575219, DOI: 10.1186/1472-6890-13-3.Peer-Reviewed Original ResearchRenal cell carcinoma tumorsMetastatic tumorsCarcinoma tumorsMetastatic specimensPredictive biomarker developmentFGF-R1Predictive biomarker testingRenal cell carcinomaTissue microarray blocksResultsNo significant differencesKi67-positive cellsMore Ki67-positive cellsSignificant differencesCell carcinomaBiomarker testingPDGF-RβMicroarray blocksPositive cellsQuantitative immunofluorescence methodVEGF-R3VEGF-R1Expression of targetsTumorsImmunofluorescence methodPrimary specimens
2010
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
Parisi F, González A, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y. Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Research 2010, 12: r66. PMID: 20809974, PMCID: PMC3096952, DOI: 10.1186/bcr2633.Peer-Reviewed Original ResearchConceptsNottingham Prognostic IndexClinico-pathological variablesPrognostic indexCox modelPrognostic modelMultivariate Cox regression modelEarly-stage breast cancerBreast cancer patient cohortsAdjuvant chemotherapy decisionsMultivariate Cox modelStage breast cancerCox regression modelCancer patient cohortsTime-dependent areaBreast cancer prognostic modelsCancer prognostic modelsNPI groupOncotype DXPatient cohortChemotherapy decisionsPrognostic markerBackward selection procedureBreast cancerQuantitative immunofluorescence methodImmunofluorescence method